Form 8-K ImmunoCellular Therapeut For: Feb 25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 25, 2016

 

 

IMMUNOCELLULAR THERAPEUTICS, LTD.

(Exact name of Company as specified in its charter)

 

 

 

Delaware		001-35560		93-1301885
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

23622 Calabasas Road, Suite 300

        Calabasas, California 91302        

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (818) 264-2300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 25, 2016, ImmunoCellular Therapeutics, Ltd. (the “Company”) and Dr. John Yu entered into an Amended and Restated Independent Contractor Services Agreement (“Agreement”), which is effective as of February 1, 2016 and supersedes the previous agreement dated October 1, 2015, which was previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 7, 2015. Under the Agreement, Dr. Yu will continue providing consulting services to the Company, including supporting the execution of the phase 3 clinical trial of ICT-107 and assisting with the evaluation and acquisition of outside technology. Dr. Yu will receive a fee of $5,000 per month. The term of the Agreement expires on July 31, 2016, and may be terminated by either party upon 30 days prior written notice. Either party may also terminate the Agreement immediately upon written notice to the other party upon a material breach of the Agreement.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 2, 2016				IMMUNOCELLULAR THERAPEUTICS, LTD.
				By:		/s/ Andrew Gengos
						Andrew Gengos
						President and Chief Executive Officer

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bureau Veritas: Strong Start to the Year; 2024 Outlook Confirmed
• Form 8.5 (EPT/RI) - musicMagpie Plc
• u-blox Secures Significant Project Wins in the Robotic Lawnmower Market With its High-Precision Positioning Technology